- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Coeliac Disease.
Displaying page 1 of 1.
EudraCT Number: 2020-002307-18 | Sponsor Protocol Number: 2020-002307-18 | Start Date*: 2021-02-10 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: A phase IIa, double-blind, randomised, placebo-controlled study on the efficacy and tolerability of a 14-day treatment with teriflunomide 14 mg tablets vs. placebo in subjects with well-controlled ... | |||||||||||||
Medical condition: Coeliac disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000697-20 | Sponsor Protocol Number: GE-GRANOANTICO-2008 | Start Date*: 2008-04-15 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: PHASE II TRIAL TO EVALUATE EFFICACY AND SECURITY OF ACUTE INTAKE OF GLUTEN DERIVED FROM TRITICUM MONOCOCCUM IN PATIENTS AFFECTED BY CELIAC DISEASE: THE "ANCIENT WHEAT" PROJECT | |||||||||||||
Medical condition: Celiac disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023127-23 | Sponsor Protocol Number: ALV003-1021 | Start Date*: 2010-10-25 | |||||||||||
Sponsor Name:Alvine Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2a, Double-Blind, Placebo Controlled Trial of the Efficacy, Safety and Tolerability of 6-Weeks Treatment With Varying Methods of ALV003 Administration in Patients With Well-Controlled Celia... | |||||||||||||
Medical condition: Celiac Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012221-10 | Sponsor Protocol Number: ALV003-0921 | Start Date*: 2009-07-21 | |||||||||||
Sponsor Name:Alvine Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2a, Double Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-week Treatment With ALV003 In Patients With Well-Controlled Celiac Disease | |||||||||||||
Medical condition: Celiac Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003450-28 | Sponsor Protocol Number: CL009_282 | Start Date*: 2007-09-04 | |||||||||||
Sponsor Name:ChemoCentryx, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease | |||||||||||||
Medical condition: Celiac Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004612-97 | Sponsor Protocol Number: CEC-4/CEL | Start Date*: 2021-08-12 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: A phase IIb, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet | |||||||||||||
Medical condition: Treatment of celiac disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Ongoing) LT (Ongoing) DE (Ongoing) NO (Ongoing) EE (Ongoing) IE (Ongoing) AT (Ongoing) IT (Ongoing) SE (Ongoing) ES (Ongoing) PL (Ongoing) BG (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000649-16 | Sponsor Protocol Number: PRV-015-002b | Start Date*: 2021-04-06 | |||||||||||
Sponsor Name:Provention Bio, Inc. | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients with Non-Responsive Celiac Disease as an Adjunct to a... | |||||||||||||
Medical condition: Celiac Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003660-31 | Sponsor Protocol Number: ALV003-1221 | Start Date*: 2013-11-27 | |||||||||||
Sponsor Name:Alvine Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, PLacebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet | |||||||||||||
Medical condition: Celiac Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) IE (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000415-14 | Sponsor Protocol Number: AT1001-011 | Start Date*: 2008-10-06 | |||||||||||
Sponsor Name:Alba Therapeutics | |||||||||||||
Full Title: Ensayo de fase IIb, aleatorizado, doble ciego, controlado con placebo, para el tratamiento de la enfermedad celíaca activa con AT-1001 | |||||||||||||
Medical condition: Enfermedad celiaquia activa | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005438-14 | Sponsor Protocol Number: TAK-062-2001 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:TAKEDA | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten... | |||||||||||||
Medical condition: Active Celiac Disease in subjects attempting a Gluten-Free Diet | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) ES (Temporarily Halted) Outside EU/EEA NL (Ongoing) BE (Ongoing) PL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001656-41 | Sponsor Protocol Number: TCeD21 | Start Date*: 2022-12-07 |
Sponsor Name:Topas Therapeutics GmbH | ||
Full Title: A double-blind, randomized, placebo-controlled, phase 2a study to evaluate the safety, tolerability, and pharmacodynamic (PD) effects of two infusions of escalating doses of TPM502 in adults diagno... | ||
Medical condition: Coeliac disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Ongoing) FI (Ongoing) DE (Ongoing) NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006651-39 | Sponsor Protocol Number: 111103 | Start Date*: 2008-12-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®) when administered intramuscular... | ||
Medical condition: No medical condition will be investigated in this study. The study will follow vaccinated females and collect safety data focussing on autoimmune diseases, pregnancy outcomes and SAEs considered to... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-003543-30 | Sponsor Protocol Number: EORTC-1809-STBSG | Start Date*: 2020-12-16 | ||||||||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | ||||||||||||||||||
Full Title: A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma | ||||||||||||||||||
Medical condition: Primary high risk leiomyosarcoma or Liposarcoma of retroperitoneal space or infra-peritoneal spaces of pelvis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) SK (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) IT (Ongoing) DE (Trial now transitioned) CY (Trial now transitioned) DK (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000533-31 | Sponsor Protocol Number: 17GA001 | Start Date*: 2017-11-07 | ||||||||||||||||
Sponsor Name:Nottingham University Hospitals NHS Trust | ||||||||||||||||||
Full Title: TReatment of Irritable bowel syndrome using Titrated ONdansetron Trial | ||||||||||||||||||
Medical condition: Irritable Bowel Syndrome with Diarrhoea | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000324-17 | Sponsor Protocol Number: GA18/118305 | Start Date*: 2019-08-02 | ||||||||||||||||
Sponsor Name:University of Leeds | ||||||||||||||||||
Full Title: Amitriptyline at Low-dose and Titrated for Irritable Bowel Syndrome as Second-line Treatment (The ATLANTIS study): A Double-blind Placebo-controlled Trial | ||||||||||||||||||
Medical condition: Irritable Bowel Syndrome (IBS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001118-24 | Sponsor Protocol Number: 117276 | Start Date*: 2014-08-19 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
Full Title: A Phase III, placebo-controlled, observer-blind, randomised, multi-centre study to describe the immunogenicity and safety of GSK Biologicals’ Quadrivalent Split Virion Influenza Vaccine 2014/2015 I... | ||||||||||||||||||
Medical condition: The target population for this study is adults in stable health ≥ 50 years of age at risk for complications of influenza and pneumococcal diseases. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000811-12 | Sponsor Protocol Number: ST03 | Start Date*: 2008-01-31 | ||||||||||||||||
Sponsor Name:Medical Research Council Clinical Trials Unit | ||||||||||||||||||
Full Title: A Randomised Phase II/III trial of peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive... | ||||||||||||||||||
Medical condition: Patients with histologically verfied lower oesophageal, Siewert Type I, II or III oesophagogastric junction or gastric adenocarcinoma. Type III or gastric tumours should be stage 1b (T1N1, T2a/bN0... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.